Dolby Family Ventures — 2017 Investments
6 investments dated 2017 · listed companies and verified rows first · show all
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Michael W. Dunne(Executive Officer, Promoter)inCorey N. Fishman(Executive Officer, Director, Promoter)inJudith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)
BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)
Co-investorsBay City CapitalCanaan PartnersSofinnova VenturesAdvent Life SciencesFrazier Life SciencesSofinnova Venture Partners
Keyssa develops a tiny solid-state wireless connector that uses electromagnetic and materials technology to transfer data at up to 6 Gbits per second between devices without software drivers or setup.
Deep TechHardwareSemiconductorsCampbell, US
Eric Almgren(Executive Officer, Director)Gordon Almquist(Executive Officer)
BoardAnthony Fadell(Director)Rahul Chaturvedi(Director)Surendra Mandava(Director)Don McKinney(Director)
Co-investorsIn-Q-TelSamsung Catalyst FundAlsop Louie PartnersIntel CapitalNeuberger Berman
Lightform develops design tools for projected augmented reality, combining computer vision and hardware to enable interactive visual experiences.
AI & Machine LearningDeep TechDeveloper ToolsHardware
Co-investorsComet LabsGen CapitalPresence CapitalTuesday CapitalAnorak VenturesLevensohn Venture Partners+2 more
M3 is an open source metrics platform, originally developed by Uber's Observability team in 2014, built around a purpose-built time series database (M3DB), a query engine, and ingestion/aggregation components.
Cloud ComputingData & InfrastructureDeveloper Tools
Co-investorsCardinia Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Entasis TherapeuticsM3 Biotechnology
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.











